- Home
- FINS vs PROK Comparison
FINS vs PROK Comparison
Compare FINS & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FINS | PROK |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 433.2M | 359.1M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | FINS | PROK |
|---|---|---|
| Price | $12.79 | $1.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.40 |
| AVG Volume (30 Days) | 35.8K | ★ 1.4M |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $893,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1075.00 |
| 52 Week Low | $12.38 | $0.59 |
| 52 Week High | $13.55 | $7.13 |
Technical Indicators
Market Signals| Indicator | FINS | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 54.57 | 56.89 |
| Support Level | $12.53 | $1.73 |
| Resistance Level | $13.05 | $1.96 |
| Average True Range (ATR) | 0.18 | 0.14 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 60.47 | 49.21 |
Price Performance
Historical ComparisonAbout FINS Angel Oak Financial Strategies Income Term Trust of Beneficial Interest
Angel Oak Financial Strats Income Term Trust is a non-diversified, closed-end management investment company. The fund's objective is to seek current income with a secondary objective of total return. In pursuing its investment objective, the fund invests mainly in debt issued by financial institutions, including subordinated debt, unrated debt, senior debt, and high-yield securities.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.